- A pooled analysis of 26 observational studies found that five-year survival was significantly improved for invasive epithelial ovarian cancer patients carrying BRCA1 or BRCA2 mutations compared with noncarriers.
- Note that data on treatment differences among the heterogeneous population were not available, there were missing data, and procedures for screening for the mutations differed among the studies.
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.